Navigating Therapeutic Uncertainties: A Review of Recent Vizient Expert Panels

October 21, 2022

This activity will describe the Expert Panel process and the correct way to evaluate the use of tenecteplase vs alteplase and bupivacaine products in the expert panel process.  This will help the audience to understand how to address therapeutic uncertainties at their sites more effectively. 

Target Audience

 

Pharmacists

 

Learning Objectives

Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to: 

1.    Describe the Expert Panel process 

2.    Describe the therapeutic controversies and/or gaps in the literature around the use of tenecteplase vs alteplase in acute ischemic stroke and long-acting bupivacaine products for postsurgical analgesia 

3.    Discuss the results of the Expert Panels for tenecteplase vs alteplase in acute ischemic stroke and long-acting bupivacaine products for postsurgical analgesia
 

 

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
Course opens: 
10/21/2022
Course expires: 
12/05/2022
Event starts: 
10/21/2022 - 1:00pm CDT
Event ends: 
10/21/2022 - 2:00pm CDT

Faculty
John Schoen, PharmD, BCPS
Sr Clinical Manger, Drug Information
Vizient

Kyle Hoelting, PharmD, BCPS
Sr Clinical Manger, Drug Information
Vizient

Planning committee
Jackie Stokes, BS
Manager, Pharmacy Program 
Vizient

Gretchen Brummel, PharmD, BCPS
Consulting Solutions Director
Vizient
 

 

Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

 

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

 

Disclosure of Financial Relationships:

Absence of Relevant Financial Relationships

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

 

No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.

 

Statement of content validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

FDA Off-label/unapproved usage


Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.


Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.”
Evidence-based Content: “Low/absence of evidence-based topics are mentioned within this activity”


Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.

 

 

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

 

Designation Statement(s):

 

PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.0  ACPE credit hours.

UAN JA0006103-0000-22-069-L01-P

 

Available Credit

  • 1.00 ACPE Pharmacist
Please login or register to take this course.